2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0311
    Emodin-8-glucoside
    		Inhibitor 99.35%
    Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier.
    Emodin-8-glucoside
  • HY-N1517
    Ganoderic acid C2
    		99.72%
    Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 is the inhibitor for aldose reductase with an IC50 of 43.8 µM.
    Ganoderic acid C2
  • HY-19687
    Zopolrestat
    		Inhibitor 99.92%
    Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications.
    Zopolrestat
  • HY-129586
    Govorestat
    		Inhibitor 99.93%
    Govorestat (AT-007) is an orally active brain-penetrant aldose reductase inhibitor with an IC50 value of 100 pM. Govorestat has the potential for galactose-1-phosphate uridyl transferase deficiency research.
    Govorestat
  • HY-120208
    MK204
    		Inhibitor 99.7%
    MK204 is an aldose reductase (AR) inhibitor that can be used in diabetes research.
    MK204
  • HY-N10361
    Drupanin
    		Inhibitor 99.35%
    Drupanin is an orally active and selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC50 value of 4.8 μM, which is found in green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers.
    Drupanin
  • HY-151231
    6-Hydroxyluteolin
    		Inhibitor 99.02%
    6-Hydroxyluteolin (Compound 17) is a flavonoid derivative and also an inhibitor of Aldose reductase, with an experimental -log IC50 value of 6.690. 6-Hydroxyluteolin can be isolated from the leaves of multiple plant families, including Plantaginaceae, Globulariaceae and Labiatae. 6-Hydroxyluteolin serves as a phylogenetic marker for higher plants. 6-Hydroxyluteolin can be used in the research of diabetic cataract.
    6-Hydroxyluteolin
  • HY-109154
    Obafistat
    		Inhibitor 99.92%
    Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC50 of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4).
    Obafistat
  • HY-N0309
    Soyasaponin Ba
    		Inhibitor 99.47%
    Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications.
    Soyasaponin Ba
  • HY-N2282
    Zingiberen newsaponin
    		Inhibitor 99.68%
    Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the AKR1C1/JAK2/STAT3 pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation.
    Zingiberen newsaponin
  • HY-116239
    Zenarestat
    		Inhibitor 99.35%
    Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats.
    Zenarestat
  • HY-122917
    Danshenol A
    		Inhibitor 99.67%
    Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.
    Danshenol A
  • HY-13633
    Exisulind
    		Inhibitor 98.04%
    Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. Exisulind inhibits aldose reductase with an IC50 of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications.
    Exisulind
  • HY-16255
    Imirestat
    		Inhibitor 99.59%
    Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
    Imirestat
  • HY-106198
    Lidorestat
    		Inhibitor 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
    Lidorestat
  • HY-18967
    Caficrestat
    		Inhibitor 99.74%
    Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy.
    Caficrestat
  • HY-W414731
    N-(3-Methylphenyl)anthranilic acid
    		Inhibitor 99.82%
    N-(3-Methylphenyl)anthranilic acid is an aldo-keto reductase 1C3 (AKR1C3)and AKR1C2 inhibitor with IC50 values of 0.24 μM and 0.38 μM, respectively. N-(3-Methylphenyl)anthranilic acid shows no inhibition of COX-1 or COX-2. N-(3-Methylphenyl)anthranilic acid can be used for the research of castration resistant prostate cancer.
    N-(3-Methylphenyl)anthranilic acid
  • HY-172314
    ACHM-025
    		Activator 98.06%
    ACHM-025 is a prodrug, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. ACHM-025 can be used for the research of cancer, such as leukemia.
    ACHM-025
  • HY-N2461
    Ganoderic acid C6
    		99.70%
    Ganoderic acid C6 has aldose reductase inhibitory activity.
    Ganoderic acid C6
  • HY-162325
    WJ-39
    		Inhibitor 99.60%
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis.
    WJ-39
Cat. No. Product Name / Synonyms Application Reactivity